|本期目录/Table of Contents|

[1]张雪,徐小元.HIV/HCV 合并感染者中两类抗病毒药物相互作用的研究[J].传染病信息,2017,06:327-330.
 ZHANG Xue,XU Xiao-Yuan*.Research of drug-drug interactions between2 antiviral agents in HIV/HCV co-infected patients[J].Infectious Disease Information,2017,06:327-330.
点击复制

HIV/HCV 合并感染者中两类抗病毒药物相互作用的研究(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2017年06期
页码:
327-330
栏目:
导向与述评
出版日期:
2017-12-20

文章信息/Info

Title:
Research of drug-drug interactions between2 antiviral agents in HIV/HCV co-infected patients
作者:
张雪徐小元
100034,北京大学第一医院感染性疾病科(张雪、徐小元);450000,郑州市第六人民医院感染二科(张雪)
Author(s):
ZHANG Xue XU Xiao-Yuan*
Department of Infectious Disease, Peking University First Hospital, 100034, China; Two Department of Infectious Disease, The SixthPeople’s Hospital of Zhengzhou, 450000, China
关键词:
抗反转录病毒药物直接抗病毒药物药物- 药物相互作用
Keywords:
antiretrovirals directly acting antiviral drug-drug interactions
分类号:
R978.7;R512.91;R512.63
DOI:
10.3969/j.issn.1007-8134.2017.06.003
文献标识码:
A
摘要:
直接抗病毒药物对HIV/HCV 合并感染者及单纯HCV 感染者的疗效相当,然而药物- 药物相互作用是临床医师在选择抗病毒方案时不容忽视的问题。本文检索分析了国内外有关直接抗病毒药物与抗反转录病毒药物相互作用的文献,并对两类抗病毒药物的相互作用进行综述,以期为临床医师治疗HIV/HCV 合并感染者时选择恰当的直接抗病毒药物组合提供参考。
Abstract:
HIV/HCV co-infected patients shar the same treatment rate as HCV-monoinfected individuals with the use of directlyacting antiviral. But we should pay attention to drug-drug interactions in formulating treatment scheme. Drug-drug interactions betweenantiretrovirals and directly acting antiviral are summarized in this paper through retrieving domestic and foreign literatures, in the hopeof providing the reference for the choice of antivirus therapy for HIV/HCV co-infected patients.

参考文献/References

[1] Morlat P, Roussillon C, Henard S, et al. Causes of death amongHIV-infected patients in France in 2010 (national survey): trendssince 2000[J]. AIDS, 2014, 28(8):1181-1191.
[2] Rockstroh JK, Bhagani S. Managing HIV/hepatitis C co-infectionin the era of direct acting antivirals[J]. BMC Med, 2013, 11:234.
[3] Chen TY, Jain MK. Treatment of hepatitis C in HIV-infectedpatients: moving towards an era of all oral regimens [J]. AIDSPatient Care and STDs, 2015, 29(6):329-337.
[4] 张霞霞,徐小元. 小分子化合物抗丙型肝炎治疗新方案[J].传染病信息,2015, 28(4):197-199.
[5] European Association for the Study of the Liver. Recommendationson treatment of hepatitis C[J] .
[2015-08-01]. http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015/report/1.
[6] AASLD/IDSA. HCV guidance: recommendations fortesting,managing and treating hepatitis C [EB/OL] .
[2016-10-05].http://hcvguidelines.org/.
[7] 周建平. 药剂学[M]. 北京:化学工业出版社,2004:289.
[8] Kaur K, Gandhi MA, Slish J, et al. Drug-drug interactions amonghepatitis C virus (HCV) and human immunodefi ciency virus (HIV)medications[J]. Infect Dis Ther, 2015, 4(2):159-172.
[9] Rodriguez-Torres M, Gaggar A, Shen G, et al. Sofosbuvir forchronic hepatitis C virus infection genotype 1-4 in patients coinfectedwith HIV[J]. J Acquir Immune Defic Syndr, 2015,68(5):543-549.
[10] Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubularabnormalities in the absence of impaired glomerular function inHIV patients treated with tenofovir[J]. AIDS, 2009, 23(6):689-696.
[11] German P, Pang PS, West S, et al. Drug interactions betweendirect-acting anti-HCV antivirals sofosbuvir and ledipasvirand HIV antiretrovirals[C]. Washington: 15th InternationalWorkshop on Clinical Pharmacology of HIV & Hepatitis Therapy,2014.
[12] German P, Garrison K, Pang PS, et al. Drug interactions betweenthe anti-HCV regimen ledipasvir/sofosbuvir and ritonavir boostedprotease inhibitors plus FTC/TDF[C]. Seattle: 22nd Conferenceon Retroviruses and Opportunistic Infections, 2015.
[13] Fazel Y, Lam B, Golabi P, et al. Safety analysis of sofosbuvir andledipasvir for treating hepatitis C[J]. Expert Opin Drug Saf,2015, 14(8):1317-1326.
[14] Burgess S, Partovi N, Yoshida EM, et al. Drug interactions withdirectacting antivirals for hepatitis C: implications for HIV andtransplant patients[J]. Ann Pharmacother, 2015, 49(6):674-687.
[15] Vivancos-Gallego MJ, Moreno A, Perez-Elias MJ, et al. Real-liferenal safety of boosted TDF in HIV/HCV patients on SOF/LDV(Abstract 452)[C]. Boston: Conference on Retroviruses andOppportunistic Infections, 2016.
[16] Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. Thepharmacokinetic interactions of the HCV protease inhibitorsimeprevir (TMC435) with HIV antiretroviral agents in healthyvolunteers[C]. San Diego: Infectious Disease Society AssociationConference, 2012.
[17] Khatn A, Trinh R, Zhao W, et al. Drug-drug interactions ofombitasvir/paritaprevir/r plus dasabuvir with dolutegravir orabacavir plus lamivudine[C]. Washington: 16th InternationalWorkshop on Clinical Pharmacology of HIV and Hepatitis Therapy,2015.
[18] Piroth L, Paniez H, Taburet AM, et al. High cure rate with 24 weeksof daclatasvir-based quadruple therapy in treatment-experienced,null-responder patients with HIV/Hepatitis C virus genotype 1/4coinfection: the ANRS HC30 QUADRIH study[J]. Clin InfectDis, 2015, 61(5):817-825.
[19] Kirby B, Mathias A, Rossi S, et al. No clinically signifi cantpharmacokinetic drug interactions between sofosbuvir (GS-7977)and HIV antiretrovirals atripla, rilpivirine, darunavir/ ritonavir,or raltegravir in healthy volunteers[C]. Boston: 63rd AnnualMeeting of the American Association of the Study of Liver Diseases(AASLD), 2012.
[20] Ray GM. Antiretroviral and statin drug-drug interactions[J].Cardiol Rev, 2009, 17(1):44-47.
[21] Karageorgopoulos DE, EL-Sherif O, Bhagani S, et al. Druginteractions between antiretrovirals and new or emerging directactingantivirals in HIV/hepatitis C virus coinfection [J]. CurrOpin Infect Dis, 2014, 27(1):36-45.
[22] Lacombe K, Fontaine H, Dhiver C, et al. Real-world efficacy ofdaclatasvir and sofosbuvir, with and without Ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a Frenchearly access cohort[J]. J Acquir Immune Defic Syndr, 2017,75(1):97-107.
[23] Khatri A, Wang T, Wang H, et al. Drug–drug interactions of thedirect-acting antiviral regimen of ABT-450/r, ombitasvir, anddasabuvir with emtricitabine+tenofovir, raltegravir, rilpivirine andefavirenz [C]. Washington: 54th Interscience Conference onAntimicrobial Agents and Chemotherapy (ICAAC), 2014.
[24] Flanagan S, Crawford-Jones A, Orkin C. Simeprevir for thetreatment of hepatitis C and HIV/hepatitis C co-infection[J].Expert Rev Clin Pharmacol, 2014, 7(6):691-704.
[25] Tseng A, Wong DK. Hepatotoxicity and potential drug interactionwith ledipasvir/sofosbuvir in HIV/HCV infected patients[J]. JHepatology, 2016, 65(3):645-654.
[26] Gandhi Y, Adamczyk R, Wang R, et al. Assessment of drug–drug interactions between daclatasvir and darunavir/ritonavir orlopinavir/ritonavir[C]. Washington: The 16th InternationalWorkshop on Clinical Pharmacology of HIV and Hepatitis Therapy,2015.
[27] Bifano M, Hwang C, Oosterhuis B, et al. Assessment ofpharmacokinetic interactions of the HCV NS5A replication complexinhibitor daclatasvir with antiretroviral agents: ritonavir-boostedatazanavir, efavirenz and tenofovir[J]. Antivir Ther, 2013,18(7):931-940.
[28] Garimella T, Gandhi Y, Wang R, et al. Daclatasvir exposure alonedoes notexplain HCV relapse in HIV/HCV coinfected patientsreceiving daclatasvir plus sofosbuvir with ritonavir-boosteddarunavir in the ALLY-2 study (Abstract 728)[C]. Boston: 66thAnnual Meeting of the American Association for the Study of LiverDiseases, 2016.
[29] Kaur K, Gandhi MA, Slish J, et al. Drug-drug interactions amonghepatitis C virus (HCV) and human immunodefi ciency virus (HIV)medications[J]. Infect Dis Ther, 2015, 4(2):159-172.
[30] AASLD/IDSA/IAS-USA. Recommendations for testing, managing,and treating hepatitis C[EB/OL] .
[2015-03-19] . http://www.hcvguidelines.org.
[31] Barrail-Tran A, Vincent C, Furlan V, et al. Raltegravirpharmacokinetics in patients on asunaprevir-daclatasvir[J].Antimicrob Agents Chemother, 2015, 59(12):7903-7905.

备注/Memo

备注/Memo:
[基金项目] 国家自然科学基金(81373056);北京市科学技术委员会重大项目(D161100001716003)
[通信作者] 徐小元,E-mail: xiaoyuanxu6@163.com
更新日期/Last Update: 2017-12-20